Navigation Links
New Heart Pump Shows Promise in Trial

Smaller, simpler device can be used in more patients, expert says

WEDNESDAY, Aug. 29 (HealthDay News) -- A new kind of heart pump helped patients with heart failure so severe that their only option was a transplant, cardiologists report.

"The design is completely different from existing assist devices," said Dr. Leslie W. Miller, chief of cardiology at Washington Hospital Center, referring to the Heart Mate II that was implanted in 133 people with end-stage heart failure. "They are pulsatile, stimulating the function of the left ventricle, which injects blood into the bloodstream. This is a continuous flow device."

At six months, 75 percent of those with device were still alive, with a 12-month survival rate of 68 percent.

"The results were very positive," said Miller, lead author of a report on the trial in the Aug. 30 issue of the New England Journal of Medicine. "These patients were so sick that it was hard to get more than 75 percent survival at six months."

The device performed well mechanically, Miller said. And there was no increased incidence of blood clotting or similar problems when compared to older generations of such devices.

Data from the trial is being submitted to the U.S. Food and Drug Administration by Thoratec, the California company that plans to market the device and funded the trial. An FDA expert panel will consider whether the agency will approve the device as a bridge to heart transplants.

Another study of the device as a permanent implant for people with less severe heart failure has just been completed, and that data will also be submitted to the FDA, Miller said.

The device "looks like a flashlight," he said. "It weighs about 14 grams, and is about a fifth the size of existing devices. It is also silent in operation."

That small size "will open the door for use in more patients," said Dr. Kenneth L. Baughman, a professor of medicine and cardiology at Brigham and Women's Hospital in Boston and co-author of an accompanying editorial. "It can be used for support in women and younger adults."

The continuous flow pump "offers a different kind of support," he said. "It is smaller in size with fewer moving parts."

In fact, the device has just one moving part, the rotor that transports blood, Miller said.

The new pump does not do away with the problems that have accompanied older devices, Baughman said. "There still are problems such as thromboembolisms [clots], bleeding and infection," he said. "These are not eliminated, but they do not occur at higher levels than with current devices."

The continuous flow pump does present one difficulty -- determining blood pressure, Baughman said. Because of the way the device works, it does not provide the systolic and diastolic blood pressure reading that are a constant in heart monitoring.

"And what is not known is what happens to the body over time," when a continuous flow pump is implanted, Baughman said. "We'll just have to wait and see how it works out over time."

More information

The workings of the current generation of assist devices are described by the American Heart Association.

SOURCES: Leslie W. Miller, M.D., chief, cardiology, Washington Hospital Center, Washington, D.C.; Kenneth L. Baughman, M.D., professor, medicine and cardiology, Brigham and Women's Hospital, Boston; Aug. 30, 2007, New England Journal of Medicine

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Duec to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Starvation in pregnant women can cause heart disease to their children
11. Individuals with sleep related breathing disorders more prone to heart disease
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: